Adding a LAMA to ICS/LABA Therapy

A Meta-analysis of Triple Combination Therapy in COPD
Published:January 17, 2019DOI:https://doi.org/10.1016/j.chest.2018.12.016

      Background

      Inhaled corticosteroid (ICS)/long-acting β 2-agonist (LABA) combination is commonly prescribed to treat COPD; therefore, we performed a meta-analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to ICS/LABA combination in COPD.

      Methods

      Studies were identified by searching in different databases the randomized controlled trials that investigated the effect of ICS/LABA/LAMA combination in COPD. The primary end points were the effect of triple therapy on trough FEV 1, risk of acute exacerbation of COPD (AECOPD), and risk of cardiovascular serious adverse events (SAEs), compared with ICS/LABA combination. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the quality of evidence.

      Results

      Thirteen randomized controlled trials including 15,519 patients with COPD (ICS/LABA/LAMA combination, 53.1%; ICS/LABA combination, 46.9%) were meta-analyzed. ICS/LABA/LAMA combination improved trough FEV 1 (mean difference, +104.86 mL; 95% CI, 86.74-122.99; high quality of evidence) and protected against AECOPD (relative risk, 0.78; 95% CI, 0.71-0.85; high quality of evidence) vs ICS/LABA combination. For every approximately four patients treated with triple therapy, one increased FEV 1 > 100 mL, and approximately 26 patients had to be treated for 1 year with ICS/LABA/LAMA combination to prevent one AECOPD, compared with ICS/LABA combination. Adding a LAMA to ICS/LABA therapy did not modulate the risk of cardiovascular SAEs (moderate quality of evidence).

      Conclusions

      Triple therapy provides significant clinical benefit in patients with COPD on ICS/LABA combination. ICS/LABA therapy can be escalated to triple therapy without a real risk to increase cardiovascular SAEs when a LAMA is added to the combination.

      Trial Registry

      ClinicalTrials.gov; No.: CRD42018095300; URL: www.clinicaltrials.gov.

      Key Words

      Abbreviations:

      AECOPD ( risk of acute exacerbation of COPD), GRADE ( Grading of Recommendations Assessment, Development, and Evaluation), HRQoL ( health-related quality of life), ICS ( inhaled corticosteroid), LABA ( long-acting β2-agonist), LAMA ( long-acting muscarinic receptor antagonist), MCID ( minimal clinically important difference), MD ( mean difference), NNT ( number needed to treat), PICO ( patient problem, intervention, comparison, and outcome), RCT ( randomized controlled trial), RR ( relative risk), SAE ( serious adverse event), SGRQ ( St. George’s Respiratory Questionnaire), TDI ( transitional dyspnea index)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vogelmeier C.F.
        • Criner G.J.
        • Martinez F.J.
        • et al.
        Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD Executive Summary.
        Eur Respir J. 2017; 49: 1750214
        • Global Initiative for Chronic Obstructive Lung Disease
        Global strategy for diagnosis, management, and prevention of COPD – 2019 report.
        • Price D.
        • Miravitlles M.
        • Pavord I.
        • et al.
        First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.
        NPJ Prim Care Respir Med. 2016; 26: 16061
        • Bogart M.
        • Stanford R.H.
        • Reinsch T.
        • Hull M.
        • Buikema A.
        • Hulbert E.
        Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: a retrospective study.
        Respir Med. 2018; 142: 73-80
        • Casas A.
        • Montes de Oca M.
        • Menezes A.M.
        • et al.
        Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
        Int J Chron Obstruct Pulmon Dis. 2018; 13: 1545-1556
        • Lipworth B.
        • Kuo C.R.
        • Jabbal S.
        Current appraisal of single inhaler triple therapy in COPD.
        Int J Chron Obstruct Pulmon Dis. 2018; 13: 3003-3009
        • Cazzola M.
        • Rogliani P.
        • Calzetta L.
        • Matera M.G.
        Triple therapy versus single and dual long-acting bronchodilator therapy in chronic obstructive pulmonary disease: a systematic review and meta-analysis.
        Eur Respir J. 2018; 52 (pii:1801586)
        • Rojas-Reyes M.X.
        • Garcia Morales O.M.
        • Dennis R.J.
        • Karner C.
        Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease.
        Cochrane Database Syst Rev. 2016; : CD008532
        • Kew K.M.
        • Dias S.
        • Cates C.J.
        Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
        Cochrane Database Syst Rev. 2014; 3: CD010844
        • Simeone J.C.
        • Luthra R.
        • Kaila S.
        • et al.
        Initiation of triple therapy maintenance treatment among patients with COPD in the US.
        Int J Chron Obstruct Pulmon Dis. 2017; 12: 73
        • Moher D.
        • Shamseer L.
        • Clarke M.
        • et al.
        Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
        System Rev. 2015; 4: 1
        • Schardt C.
        • Adams M.B.
        • Owens T.
        • Keitz S.
        • Fontelo P.
        Utilization of the PICO framework to improve searching PubMed for clinical questions.
        BMC Med Inform Decis Mak. 2007; 7: 16
        • Calverley P.M.A.
        • Magnussen H.
        • Miravitlles M.
        • Wedzicha J.A.
        Triple therapy in COPD: what we know and what we don't.
        COPD. 2017; 14: 648-662
        • Singh D.
        • Corradi M.
        • Spinola M.
        • et al.
        Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
        Int J Chron Obstruct Pulmon Dis. 2017; 12: 2917-2928
        • Calzetta L.
        • Rogliani P.
        • Matera M.G.
        • Cazzola M.
        A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD.
        Chest. 2016; 149: 1181-1196
        • Cazzola M.
        • Rogliani P.
        • Calzetta L.
        • Hanania N.A.
        • Matera M.G.
        Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis.
        COPD. 2017; 14: 552-563
        • Becker B.J.
        • Wu M.-J.
        The synthesis of regression slopes in meta-analysis.
        Stat Sci. 2007; 22: 414-429
        • Guyatt G.
        • Oxman A.D.
        • Akl E.A.
        • et al.
        GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
        J Clin Epidemiol. 2011; 64: 383-394
        • Pedder H.
        • Sarri G.
        • Keeney E.
        • Nunes V.
        • Dias S.
        Data extraction for complex meta-analysis (DECiMAL) guide.
        System Rev. 2016; 5: 212
        • Lipson D.A.
        • Barnhart F.
        • Brealey N.
        • et al.
        Once-daily single-inhaler triple versus dual therapy in patients with COPD.
        N Engl J Med. 2018; 378: 1671-1680
        • Ferguson G.T.
        • Rabe K.F.
        • Martinez F.J.
        • et al.
        Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
        Lancet Respir Med. 2018; 6: 747-758
        • Lipson D.A.
        • Barnacle H.
        • Birk R.
        • et al.
        FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2017; 196: 438-446
        • Singh D.
        • Papi A.
        • Corradi M.
        • et al.
        Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
        Lancet. 2016; 388: 963-973
        • Sousa A.R.
        • Riley J.H.
        • Church A.
        • Zhu C.Q.
        • Punekar Y.S.
        • Fahy W.A.
        The effect of umeclidinium added to inhaled corticosteroid/long-acting beta2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
        NPJ Prim Care Respir Med. 2016; 26: 16031
        • Siler T.M.
        • Kerwin E.
        • Singletary K.
        • Brooks J.
        • Church A.
        Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: Results of two randomized, double-blind studies.
        COPD. 2016; 13: 1-10
        • Frith P.A.
        • Thompson P.J.
        • Ratnavadivel R.
        • et al.
        Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
        Thorax. 2015; 70: 519-527
        • Saito T.
        • Takeda A.
        • Hashimoto K.
        • Kobayashi A.
        • Hayamizu T.
        • Hagan G.W.
        Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
        Int J Chron Obstruct Pulmon Dis. 2015; 10: 2393-2404
        • Siler T.M.
        • Kerwin E.
        • Sousa A.R.
        • Donald A.
        • Ali R.
        • Church A.
        Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
        Respir Med. 2015; 109: 1155-1163
        • Cazzola M.
        • Ando F.
        • Santus P.
        • et al.
        A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
        Pulm Pharmacol Ther. 2007; 20: 556-561
        • Singh D.
        • Brooks J.
        • Hagan G.
        • Cahn A.
        • O'Connor B.J.
        Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
        Thorax. 2008; 63: 592-598
        • Aaron S.D.
        • Fergusson D.A.
        Exaggeration of treatment benefits using the “event-based” number needed to treat.
        Can Med Assoc J. 2008; 179: 669-671
        • Cazzola M.
        • MacNee W.
        • Martinez F.J.
        • et al.
        Outcomes for COPD pharmacological trials: from lung function to biomarkers.
        Eur Respir J. 2008; 31: 416-469
        • Jones P.W.
        • Beeh K.M.
        • Chapman K.R.
        • Decramer M.
        • Mahler D.A.
        • Wedzicha J.A.
        Minimal clinically important differences in pharmacological trials.
        Am J Respir Crit Care Med. 2014; 189: 250-255
        • Bateman E.
        • Ssr authors
        Lack of clinically relevant differences between combination therapy and monotherapy in COPD.
        Eur Respir J. 2014; 43: 1204-1205
        • Magnussen H.
        • Disse B.
        • Rodriguez-Roisin R.
        • et al.
        Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
        N Engl J Med. 2014; 371: 1285-1294
        • Calzetta L.
        • Matera M.G.
        • Braido F.
        • et al.
        Withdrawal of inhaled corticosteroids in COPD: a meta-analysis.
        Pulm Pharmacol Ther. 2017; 45: 148-158
        • Guyatt G.H.
        • Oxman A.D.
        • Kunz R.
        • et al.
        GRADE guidelines 6. Rating the quality of evidence--imprecision.
        J Clin Epidemiol. 2011; 64: 1283-1293
        • Calzetta L.
        • Puxeddu E.
        • Rogliani P.
        Gender-related responsiveness to the pharmacological treatment of COPD: a first step towards the personalized medicine.
        EBioMedicine. 2017; 19: 14-15
        • Matera M.G.
        • Calzetta L.
        • Rogliani P.
        • Cesario A.
        • Cazzola M.
        New treatments for COPD in the elderly.
        Curr Pharm Des. 2014; 20: 5968-5982
        • Albano G.D.
        • Bonanno A.
        • Moscato M.
        • et al.
        Crosstalk between mAChRM3 and beta2AR, via acetylcholine PI3/PKC/PBEP1/Raf-1 MEK1/2/ERK1/2 pathway activation, in human bronchial epithelial cells after long-term cigarette smoke exposure.
        Life Sci. 2018; 192: 99-109
        • Calzetta L.
        • Rogliani P.
        • Ora J.
        • Puxeddu E.
        • Cazzola M.
        • Matera M.G.
        LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment.
        Eur Respir Rev. 2017; 26: 1-11

      Linked Article

      • Single Triple vs Dual Inhaler Therapy
        CHESTVol. 155Issue 5
        • In Brief
          We read with interest the well-conducted meta-analysis of triple therapy by Calzetta et al1 in a recent issue of CHEST comprising randomized controlled trials evaluating adding long-acting muscarinic antagonist (LAMA) to inhaled corticosteroid and long-acting beta agonist (ICS/LABA) in COPD. Their results showed that 2 long-acting bronchodilators (LAMA and LABA) are better than 1 (LABA) in terms of improving lung function, symptoms, and health status as well as reducing exacerbations.
        • Full-Text
        • PDF
      • Response
        CHESTVol. 155Issue 5
        • In Brief
          We thank Drs Lipworth and Kuo for their comments on our meta-analysis1 published in CHEST. First, we must highlight that, in our recent meta-analysis focused on triple therapy vs single and dual long-acting bronchodilator therapy in COPD,2 we found that the overall values of surface under the cumulative ranking curve, a method that we used to systematically rank order inhaled corticosteroid (ICS) and non-ICS based therapies, taking into consideration their benefits as well as their risks, favored long-acting bronchodilator/long-acting muscarinic antagonist (LABA/LAMA) combination over ICS/LABA/LAMA and LABA or LAMA alone.
        • Full-Text
        • PDF